The FDA granted approval to SK Biopharmaceuticals, Co., Ltd. and its U.S. subsidiary SK Life Science, Inc. for XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adult patients.This approval is the first time that a Korean pharmaceutical company has independently brought a compound from discovery to U.S. FDA approval. WIth our global footprint, Yourway is well positioned to support international clinical trials.